ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes
Primary result · Weight lossResult — go to the resultWeight loss relative to lispro 2.1 kgAuthors' conclusion
These results extend previous observations on the efficacy and safety of this insulin/pramlintide co-formulation. They show a beneficial effect on weight, using less mealtime insulin and without increased hypoglycaemia.
Study context
- Population
- Participants with T1D
- Participants
- 80 participants
- Comparison
- ADO09 vs insulin lispro
- Primary endpoint
- Weight loss
- Follow-up
- 16 weeks
Methodological detailstwo-arm, ambulatory
- Two-arm
- Ambulatory
Primary result
As reported in the abstract
Weight loss relative to lispro
2.1 kg
Further findings
HbA1c
- Mean HbA1c 7.7% in both groups; did not change during treatment
Insulin doses
- Prandial insulin dose reduced with ADO09
- 21%
- Basal insulin dosage not modified
Safety
- GI symptoms more frequent with ADO09
- No clear difference in hypoglycaemia
Original publication
ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes. Diabetes Obes Metab. Published 7 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →